ClinicalTrials.gg
RecruitingNCT06991075TENSUpdated Sep 18, 2026

Transcutaneous Electrical Nerve Stimulation for Pain Mitigation During Intrauterine Device Placement

An interventional study of High frequency transcutaneous electrical nerve stimulation in Pain, sponsored by Medical University of South Carolina. Recruiting at 1 site in United States. Open to female participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-09-18.

Sponsored by Medical University of South Carolina · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Dec 2025; still recruiting 11 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
86
Allocation
Randomized
Ages
18 Years and older
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 15 studies in Pain by Medical University of South Carolina — 3 open to participants now, 3 under way, none of them phase 3. Pain · Medical University of South Carolina.

Planned enrollment
2nd of 15
86 · median 15
Started
2025
the only one that year
No phase
11 of 15
3 open now
Registered
14th of 15
by date

Among the 15 studies in Pain by Medical University of South Carolina, this one is the 2nd largest by planned enrollment, is the only one that started in 2025, is one of 11 with no phase, and was the 14th registered.

Pain

10,076 studies on the registry are indexed under Pain; 1,648 are open to participants now.

Browse Pain studies →

Open to participants now

3 of the 15 studies in Pain by Medical University of South Carolina are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

Where they have run

Who these studies take

Of the 930 Pain studies recruiting now, 384 (41%) set no upper age limit and 434 (47%) stop at 75 or younger; 146 take children under 18; 220 take healthy volunteers.

This study: 18 Years and older · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 15 studies in Pain by Medical University of South Carolina, or all of them as a file.
02

Study summary

Investigators are conducting a study to determine whether high frequency transcutaneous electrical nerve stimulation (hfTENS) is effective at reducing pain in women having an IUD inserted.

Read the detailed description

The intrauterine device (IUD) is a highly effective contraceptive method with increasing utilization in the last decade. The procedure to both place and remove an IUD is typically performed in the ambulatory gynecologic clinic. Pain associated with IUD insertion is variably described, and evidence suggests that physicians underestimate the severity of pain patients experience with this procedure. Studies have quantified the experience of pain using visual analog scales, demonstrating moderate insertional pain ranging from 5 to 7 out of 10 cm (equivalent to 50-70 out of 100 mm) on VAS. Increasingly, both academic and lay media reports highlight that traumatic nature of a painful IUD placement and call providers to acknowledge and address the pain of IUD placement in a meaningful way.

To date, research has not identified a highly effective strategy to reduce pain during IUD placement. Transcutaneous electrical nerve stimulation (TENS) is a low-cost, low-risk, nonpharmacologic intervention for pain management. The handheld device works by transmitting an electronically generated topical stimulus to a specified area on the body to alter response to pain signals and promote endogenous endorphin release for pain reduction. High frequency TENS (>50 Hz; "hfTENS") significantly reduces pain associated with dysmenorrhea and a range of outpatient gynecologic procedures, including medication abortion, hysteroscopy, and uterine aspiration. This study evaluates an intervention to address pain during IUD placement in the ambulatory setting.

03

Conditions studied

  • Pain

Browse trials for

Keywords

  • Obstetrics and Gynecology
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Provision of signed and dated form for IUD Insertion
  • Stated willingness to comply with all study procedures
  • English speaking individuals aged 18 years or older
  • Presenting for IUD initiation during ambulatory care visit at MUSC Women's Health
  • Opting for either LNG 52mg or copper T380A IUD

Exclusion criteria

Exclusion Criteria:

  • to IUD initiation (i.e. pregnancy, current pelvic infection, distorted uterine anatomy)
  • Contraindication or allergy to ibuprofen
  • History of a chronic pain disorder
  • Recent opioid use in the previous 30 days
  • History of a cardiac arrhythmia
  • History of heart disease (i.e. atrial fibrillation, congestive heart failure)
  • Presence of an implantable device with an electrical discharge (i.e. pacemaker)
  • > 50 (class IV obesity)
  • History of TENS use
  • Planned pain intervention outside standard of care (i.e. paracervical block, misoprotol) OR preprocedure use of non-standard pain medication (i.e. benzodiazepines, marijuana, muscle relaxers, gabapentin, benadryl)
  • History of epilepsy
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Care provider)
Enrollment
86 participants (estimated)

Study arms

  • Active comparator
    Active TENS

    A TENS 7000 digital TENS unit will be used. A research staff member will apply TENS pads to specified areas on the lower abdomen and lower back corresponding to T10-11 and S2-4 dermatomes. For the active treatment group, the device will be set to 80 Hz (hfTENS) and device intensity (0-8) will be titrated to patient comfort, as is the standard protocol for TENS use.

    Device: High frequency transcutaneous electrical nerve stimulation

  • Placebo comparator
    Placebo TENS

    A TENS 7000 digital TENS unit will be used. A research staff member will apply TENS pads to specified areas on the lower abdomen and lower back corresponding to T10-11 and S2-4 dermatomes. The TENS device will not be turned on.

    Device: High frequency transcutaneous electrical nerve stimulation

Interventions

  • DeviceHigh frequency transcutaneous electrical nerve stimulation

    TENS 7000 digital TENS unit will be used.

06

What researchers measure

Primary outcomes

  1. Pain scores reported at IUD insertion

    Pain scores at time of IUD insertion as measured by VAS scores between TENS and placebo groups

    Time frame: From enrollment until 5 minutes after procedure completion

07

Study locations

1 of 1 sites recruiting
  • MUSC Women's Health- Cannon Street
    Charleston, South Carolina 29425, United States
    Recruiting
    • Angela Dempsey, MD · Contact843-792-5300
    • Angela Dempsey, MD · Sub investigator
08

References and documents

Individual participant data

Plan to share: No — De-identified individual participant data will be analyzed according to the statistical plan for manuscript preparation and journal publication. Individual participant data will be shared within the study team including our collaborators at Icahn School of Medicine at Mount Sinai. Also, IPD will be shared with the IRB according to institutional guidelines.

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Dec 2025 (actual). Primary completion is estimated for Aug 2027, 20 months after the start.

Of 3,749 non-industry interventional studies with no phase under Pain, half reached primary completion within 10 months of starting (the median), counting those still running; a quarter within 4 and three quarters within 23. This study's planned 20 months is above that.

Counting every sponsor, half of 3,848 studies reached it within 10 months; a quarter within 4 and three quarters within 23.

How these figures are worked out, and which studies are left out of them.

Registered
May 22, 2025
First posted
May 25, 2025
StartActual
Dec 1, 2025
Primary completionEst.
Aug 2027
CompletionEst.
Nov 2027
Last update
Sep 18, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 18, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06991075
Responsible party
Michelle Meglin (Associate Professor-Faculty, Medical University of South Carolina) — Principal investigator
First posted
May 25, 2025
Start date
Dec 1, 2025
Primary completion
Aug 2027 (estimated)
Completion
Nov 2027 (estimated)
Last update
Sep 18, 2026

Study contacts

Jesslyn Payne
Contact
paynej@musc.edu
(843)-792-7525
Michelle Meglin, MD
Contact
meglin@musc.edu
843-792-4026

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion